Caribou Biosciences, Inc. (CRBU): Total Liabilities
$53.19M
As of 2025-12-31
$44.67M
As of 2026-06-30
-10.0%
3-year compound annual growth
+24.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.19M | -11.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $60.36M | -5.4% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $63.81M | -12.5% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $72.89M | +33.7% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $54.53M | +200.3% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $18.16M | n/a | 2022-03-21, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
Compare CRBU, TCRX, ACOG, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗